Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Table 1 Patient and tumor characteristics at time of transarterial radioembolization procedures

Parameters	All procedures (n = 169)	TARE_alone (n = 63)	TARE_sorafenib (n = 81)	TARE_no_sorafenib (n = 25)
ECOG
0	82 (48.5)	32 (50.8)	40 (49.4)	10 (40)
1	82 (48.5)	28 (44.4)	40 (49.4)	14 (56)
2	4 (2.4)	2 (3.2)	1 (1.2)	1 (4)
3	1 (0.6)	1 (1.6)	0	0
BCLC
A	5 (3)	5 (7.9)	0	0
B	45 (26.6)	26 (41.3)	16 (19.8)	3 (12)
C	118 (69.8)	31 (49.2)	65 (80.2)	22 (88)
D	1 (0.6)	1 (1.6)	0	0
Child-pugh class
A	157 (92.9)	57 (90.5)	78 (96.3)	22 (88.0)
B	12 (7.1)	6 (9.5)	3 (3.7)	3 (12.0)
AFP1
< 400 ng/mL	118 (70.2)	54 (85.7)	52 (64.2)	12 (50)
≥ 400 ng/mL	50 (29.8)	9 (14.3)	29 (35.8)	12 (50)
Cirrhosis
Absence	52 (30.8)	15 (23.8)	29 (35.8)	8 (32)
Presence	117 (69.2)	48 (76.2)	52 (64.2)	17 (68)
Infiltrative tumor
Absence	133 (78.7)	63 (100)	58 (71.6)	12 (48)
Presence	36 (21.3)	0	23 (28.4)	13 (52)
Vascular invasion2
Absence	131 (78)	63 (100)	56 (70)	12 (48)
Presence	37 (22)	0	24 (30)	13 (52)
Extrahepatic disease
Absence	137 (81.1)	63 (100)	60 (74.1)	14 (56)
Presence	32 (18.9)	0	21 (25.9)	11 (44)
Number of tumors
Single	28 (16.6)	12 (19)	9 (11.1)	7 (28)
Multiple	141 (83.4)	51 (81)	72 (88.9)	18 (72)
Lobar involvement
Unilobar	63 (37.3)	33 (52.4)	22 (27.2)	8 (32)
Bilobar	106 (62.7)	30 (47.6)	59 (72.8)	17 (68)
Intrahepatic tumor
≤ 50%	116 (68.6)	63 (100)	37 (45.7)	16 (64)
> 50%	53 (31.4)	0	44 (54.3)	9 (36)
TARE procedures
1	151 (89.3)	56 (88.9)	71 (87.7)	24 (96)
2	16 (9.5)	7 (11.1)	8 (9.9)	1 (4)
3	2 (1.2)	0	2 (2.5)	0

¹Unavailable AFP in one TARE_no_sorafenib patient.

²Unavailable vascular invasion in one TARE_sorafenib patient.

Values represent number of procedures (%). TARE: Transarterial radioembolization; ECOG: Eastern cooperative oncology group; BCLC: Barcelona clinic liver cancer; AFP: Alpha-fetoprotein.